glp 1 studies 2025 GLP-1 Agonists Market Report 2025-2033, By Product, Molecule, and Geo GLP-1 trends 2025: real-world data,

*Correspondence: Adonis Sfera, [email protected] Specialty section: This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

In recent years, significant advances have been made in the pharmaceutical field for treating obesity, particularly through Novo Nordisks development of the GLP-1 receptor agonist semaglutide , which has had a major impact and revolutionized treatment

News-Medical, viewed 18 July 2026,

Cellular Reprogramming, 13 (6), 465472

To their excitement, they found that MPGF was indeed differentially processed in the gut, but not in the pancreas, to yield two GLPs (ref

An Alternative Low-Cost Option: Kongo If brand-name GLP-1s are out of reachwhether due to cost, insurance restrictions, or accesscompounded medications offer another path forward